KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Debt (2020 - 2025)

Historic Total Debt for AbCellera Biologics (ABCL) over the last 6 years, with Q1 2025 value amounting to $8.8 million.

  • AbCellera Biologics' Total Debt fell 8294.61% to $8.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.8 million, marking a year-over-year decrease of 8294.61%. This contributed to the annual value of $8.1 million for FY2024, which is 8397.82% down from last year.
  • As of Q1 2025, AbCellera Biologics' Total Debt stood at $8.8 million, which was down 8294.61% from $8.1 million recorded in Q4 2024.
  • In the past 5 years, AbCellera Biologics' Total Debt registered a high of $54.9 million during Q2 2023, and its lowest value of $8.1 million during Q4 2024.
  • In the last 5 years, AbCellera Biologics' Total Debt had a median value of $27.5 million in 2022 and averaged $30.0 million.
  • As far as peak fluctuations go, AbCellera Biologics' Total Debt surged by 19599.03% in 2022, and later plummeted by 8397.82% in 2024.
  • Quarter analysis of 5 years shows AbCellera Biologics' Total Debt stood at $22.9 million in 2021, then soared by 92.77% to $44.2 million in 2022, then grew by 14.17% to $50.5 million in 2023, then plummeted by 83.98% to $8.1 million in 2024, then grew by 8.46% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q1 2025, $8.1 million for Q4 2024, and $20.2 million during Q3 2024.